Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02777242 · ClinicalTrials.gov registry record · Phase 2
Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism
A Phase 2 study, sponsored by Antares Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT02777242 is a Phase 2 study that has completed, run by Antares Pharma. The registered enrollment target is 66 participants.
The verdict
NCT02777242, a Phase 2 study, has completed, sponsored by Antares Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
Evaluation of the safety and tolerability of testosterone enanthate (TE) following a single dose via QuickShot® Testosterone (QST) when administered by intended users in a usability study.
Interventions
- COMBINATION_PRODUCT Testosterone enanthate auto-injector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2016-06 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02777242
The ClinicalTrials.gov registry entry for NCT02777242 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Antares Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Testosterone enanthate auto-injector is the first listed.
NCT02777242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02777242 about?
NCT02777242 is a clinical study titled "Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism". Evaluation of the safety and tolerability of testosterone enanthate (TE) following a single dose via QuickShot® Testosterone (QST) when administered by intended users in a usability study.
What is the current status of trial NCT02777242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2016-06. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02777242?
The interventions under investigation include: Testosterone enanthate auto-injector (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT02777242?
This trial is sponsored by Antares Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.